News

The preliminary data to date has indicated that Triolex is safe and well tolerated at all doses studied. In addition, the preliminary data thus far suggest that Triolex

MLN3126 is a selective antagonist of CCR9, a chemokine receptor known to be important in the migration of inflammatory cells into the gastrointestinal tract. MLN3126 expands the company’s

The multi-year agreement stipulates that the distributor must meet a defined set of sales performance criteria. NIR Diagnostics is currently not disclosing the name of the distributor pending

This IgM antibody recognizes a unique cell surface marker that is expressed on Q-Cells (neural glial cells). On successful completion of the production, Q Therapeutics will utilize the

The FDA Center for Drug Evaluation and Research (CDER) acknowledged that complete response, which was the primary endpoint in the pivotal trial, was an appropriate endpoint for assessing

Under the agreement, both Innovative Biosensors (IBI) and Universal Detection Technology (UDT) will market and distribute their partner’s biodetection equipment, in addition to their own products, broadening their

Preliminary results from the first two of three cohorts demonstrate that the oral dosing regimens tested so far produce robust reductions in plasma viral load and are well

This follows extensive laboratory experimentation and includes the recent demonstration of activity in an in-vivo model of myeloproliferative disease. CYT387 is claimed to possess an excellent selectivity profile

Under the terms of the agreement, Desitin will oversee, and be responsible for the expenses related to, all clinical development, regulatory approvals and commercialization efforts required to market